These data confirm that the clinical amelioration of the symptoms of SSc observed in mice following DMF treatment are related to the enhanced transcription of Nrf2 and its downstream target genes HO-1 and GCL triggering a cytoprotective and antioxidant response. This evidence concerns the gene HMOX1 and systemic sclerosis.